Brainomix, an Oxford University spinout founded in 2010, is revolutionizing stroke care with its AI-driven technology. The company, emerging from the University’s preclinical stroke lab, specializes in digital health innovations. Co-founded by Dr. Michalis Papadakis, now CEO, Brainomix has created the e-Stroke platform, a cutting-edge tool that leverages AI algorithms to enhance the accuracy and speed of stroke diagnosis and treatment. By analyzing CT scans, e-Stroke provides immediate, detailed insights into brain damage, facilitating faster and more effective decision-making by healthcare professionals.
Proven to significantly reduce patient discharge times and triple the rate of functional independence post-stroke, e-Stroke is now a critical component in over 30 healthcare systems worldwide, attracting over £30m in funding. The platform processes a patient scan every five minutes, delivering results in just 60 seconds.
Expanding its technological prowess, Brainomix has also ventured into AI solutions for lung disease and cancer, establishing itself as a pioneer in the health data space. With strokes affecting approximately 100,000 individuals in the UK annually and millions worldwide, Brainomix’s innovations are setting new standards in patient care and outcomes, exemplifying the transformative impact of academic research on global health challenges.
On Brainomix, Papadakis, said:
“In 2023 we were delighted to receive FDA approval to take our e-ASPECTS tool to the US, where more than 800,000 people suffer a stroke each year. This tool, part of the Brainomix 360 package of AI technologies, supports physicians who are making time-sensitive, critical decisions around transfer and treatment, strengthening networks and facilitating an improved stroke service.”
